2/16/2012

The FDA has cleared StemCells' experimental neural stem cell therapy for use in a Phase I/II clinical trial for dry age-related macular degeneration. The open-label, dose-escalation trial will involve 16 patients. Results of a preclinical study showed the stem cell treatment can protect photoreceptors and save vision in an animal model of retinal disease.

Full Story:
Modern Medicine

Related Summaries